Sigyn Therapeutics Inc logo

SIGY - Sigyn Therapeutics Inc Share Price

$1.32 0.0  0.0%

Last Trade - 02/12/20

Sector
Healthcare
Size
Micro Cap
Market Cap £33.5m
Enterprise Value £35.0m
Revenue £7.38k
Position in Universe 5014th / 6444
Bullish
Bearish
Unlock SIGY Revenue
Momentum
Relative Strength (%)
1m -38.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -55.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.043 3.29 1.80 0.038 0.028 0.14 +27.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, SigynTherapeutics Inc revenues decreased 97% to $5K. Net lossbefore extraordinary items decreased 5% to $419K. Revenuesreflect a decrease in demand for the Company's products andservices due to unfavorable market conditions. Lower netloss reflects General and administrative decrease of 61% to$191K (expense), Advertising and marketing expensesdecrease of 91% to $1K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SIGY Revenue Unlock SIGY Revenue

Net Income

SIGY Net Income Unlock SIGY Revenue

Normalised EPS

SIGY Normalised EPS Unlock SIGY Revenue

PE Ratio Range

SIGY PE Ratio Range Unlock SIGY Revenue

Dividend Yield Range

SIGY Dividend Yield Range Unlock SIGY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SIGY EPS Forecasts Unlock SIGY Revenue
Profile Summary

Sigyn Therapeutics, Inc., formerly Reign Resources Corporation, is a development-stage therapeutic medical technology company. The Company is focused on treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. The Company’s Sigyn Therapy is a blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include inflammatory cytokines, cytokine aggregates, endotoxin and larger CytoVesicles that transport cytokines and other inflammatory cargos. The Company’s treatment pipeline opportunities includes virus induced Cytokine Storm (VICS), bacteria induced Cytokine Storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated December 15, 2014
Public Since January 28, 2016
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 34,186,169
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SIGY Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SIGY
Upcoming Events for SIGY
Frequently Asked Questions for Sigyn Therapeutics Inc
What is the Sigyn Therapeutics Inc share price?

As of 02/12/20, shares in Sigyn Therapeutics Inc are trading at $1.32, giving the company a market capitalisation of £33.5m. This share price information is delayed by 15 minutes.

How has the Sigyn Therapeutics Inc share price performed this year?

Shares in Sigyn Therapeutics Inc are currently trading at $1.32 and the price has moved by 6.67% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sigyn Therapeutics Inc price has moved by -7.09% over the past year.

What are the analyst and broker recommendations for Sigyn Therapeutics Inc?

There are no analysts currently covering Sigyn Therapeutics Inc.

When will Sigyn Therapeutics Inc next release its financial results?

Sigyn Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Sigyn Therapeutics Inc dividend yield?

Sigyn Therapeutics Inc does not currently pay a dividend.

Does Sigyn Therapeutics Inc pay a dividend?

Sigyn Therapeutics Inc does not currently pay a dividend.

When does Sigyn Therapeutics Inc next pay dividends?

Sigyn Therapeutics Inc does not currently pay a dividend.

How do I buy Sigyn Therapeutics Inc shares?

To buy shares in Sigyn Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sigyn Therapeutics Inc?

Shares in Sigyn Therapeutics Inc are currently trading at $1.32, giving the company a market capitalisation of £33.5m.

Where are Sigyn Therapeutics Inc shares listed? Where are Sigyn Therapeutics Inc shares listed?

Here are the trading details for Sigyn Therapeutics Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: SIGY
What kind of share is Sigyn Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Sigyn Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sigyn Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Sigyn Therapeutics Inc.

How can I tell whether the Sigyn Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sigyn Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 21.17%. At the current price of $1.32, shares in Sigyn Therapeutics Inc are trading at 25.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sigyn Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Sigyn Therapeutics Inc.

Who are the key directors of Sigyn Therapeutics Inc?

Sigyn Therapeutics Inc's management team is headed by:

James Joyce - CHM
Craig Roberts - CTO
Who are the major shareholders of Sigyn Therapeutics Inc?

Here are the top five shareholders of Sigyn Therapeutics Inc based on the size of their shareholding:

Osher Capital Partners, L.L.C. Corporation
Percentage owned: 9.99% (3.42m shares)
Segelman (Joseph) Individual Investor
Percentage owned: 0.44% (150k shares)
Ashikian (Michael) Individual Investor
Percentage owned: 0.27% (93.4k shares)
Crossover Capital Management, LLC Hedge Fund
Percentage owned: 0.12% (42.2k shares)
Coordinates Collection, Inc. Corporation
Percentage owned: 0.11% (36.7k shares)
Similar to SIGY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.